While much earlier in its development, the drug may be able to rival Gilead’s Trodelvy, which also targets TROP2 and showed similar response rates.

The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.

Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.

The next-generation DMD drug showed dramatic improvement on exon dystrophin and exon skipping, but small numbers and adverse events give pause.

Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.

Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.